Home > Riviste > International Angiology > Fascicoli precedenti > International Angiology 2016 August;35(4) > International Angiology 2016 August;35(4):365-8





Rivista di Angiologia

Official Journal of the International Union of Angiology, the International Union of Phlebology and the Central European Vascular Forum
Indexed/Abstracted in: BIOSIS Previews, Current Contents/Clinical Medicine, EMBASE, PubMed/MEDLINE, Science Citation Index Expanded (SciSearch), Scopus
Impact Factor 0,899




International Angiology 2016 August;35(4):365-8

lingua: Inglese

Novel oral anticoagulants in the treatment of cerebral venous thrombosis

Gergely FEHER 1, Zsolt ILLES 2, Samuel KOMOLY 3, David HARGROVES 4

1 Szigetvar Hospital, Szigetvár, Hungary; 2 University of Southern Denmark, Odense, Denmark; 3 University of Pecs, Pécs, Hungary; 4 William Harvey Hospital, Kent, UK


Cerebral venous thrombosis (CVT) is an uncommon cause of stroke with extremely diverse clinical features, predisposing factors, brain imaging findings, and outcome. Anticoagulation is the cornerstone of CVT management, however, it is not supported by high-quality evicence. Novel oral anticoagulants (NOACs) have been extensively studied in patients with deep vein thrombosis, pulmonary embolism and non-valvular atrial fibrillation. The aim of our work was to review the available evidence for NOACs in the treatment of CVT. Based on our literature search there is insufficient evidence to support the use of NOACs in CVT, although case series with rivaroxaban and dabigatran have showed promising results.

inizio pagina

Publication History

Per citare questo articolo

Corresponding author e-mail